SCHEMBL3962292

SCHEMBL3962292

CCOC(=O)c1cc2ccccc2n1CCc1ccc(Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 5/20 0.69
NOD1 Q9Y239 5/20 0.69
KDM4E B2RXH2 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
CRHBP P24387 1/20 0.63
CRHR2 Q13324 1/20 0.63
F10 P00742 3/20 0.61
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
MAPT P10636 3/20 0.57
MAPK1 P28482 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CCR2 P41597 1/20 0.55
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
TSHR P16473 1/20 0.49
SRC P12931 1/20 0.47
MCL1 Q07820 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302610 0.90 NOD2 (0.84) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL8686408 0.90 SMN1; SMN2 (0.68) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL3958983 0.85 KDM4E (0.59) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL6752352 0.82 KDM4E (0.71) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL3960926 0.82 CCR2 (0.80) F10CCR2MCL1ALDH1A1
SCHEMBL12803610 0.82 NOD2 (0.69) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL18322286 0.81 KDM4E (0.73) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL30489155 0.81 KDM4E (0.73) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL4215637 0.81 KDM4E (0.70) NOD2NOD1KDM4ESMN1; SMN2CRHBP
SCHEMBL13742183 0.81 KDM4E (0.70) NOD2NOD1KDM4ESMN1; SMN2CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451185-B1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2014-08-06 EP disclosed
US-7605134-B2 Pesticides MERIAL LIMITED (US) 2009-10-20 US disclosed
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-12 US disclosed
US-6906084-B2 Indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-14 US disclosed
US-20050043302-A1 New indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-24 US disclosed
EP-1451185-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2004-09-01 EP disclosed
US-20030199689-A1 New indole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-23 US disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 WO disclosed
EP-1314733-A1 Indole-2-carboxamides as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS F12, F5, F2 NOD2 4235/4885NOD1 2933/4885KDM4E 1568/4885
US-20030199689-A1 New indole derivatives as factor Xa inhibitors F5, F12, F2 NOD2 4293/4885NOD1 2993/4885KDM4E 1206/4885
US-20050043302-A1 New indole derivatives as factor Xa inhibitors F12, F5, F2 NOD2 4337/4885NOD1 3052/4885KDM4E 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.